You dont need to be obese to start a GLP-1. In practice, though, you doat least according to the US Food and Drug Administration, which has only approved GLP-1 drugs for people with clinical obesity or Type 2 diabetes and for people who are overweight with weight-related comorbidities
That pill is just 14 milligrams, while the tablet that the company is currently testing is 50 milligrams
Morning or evening does not significantly impact efficacy based on available research, though some users report better appetite suppression when injecting in the morning
The full retatrutide product page includes current vial pricing, batch documentation, and Janoshik test reports
Intravenous therapy may be considered under medical supervision for specific health conditions, but it carries more risks and is not recommended for cosmetic purposes by most experts